(Q43712751)

26 November 2017

Cost estimation of cardiovascular disease events in the US. (English)

1 reference

26 November 2017

cardiovascular disease

1 reference

Amy K O'Sullivan

1

1 reference

26 November 2017

Jaime Rubin

2

1 reference

26 November 2017

Joshua Nyambose

3

1 reference

26 November 2017

Andreas Kuznik

4

1 reference

26 November 2017

David J Cohen

5

1 reference

26 November 2017

David Thompson

6

1 reference

26 November 2017

language of work or name

1 reference

1 August 2011

1 reference

26 November 2017

1 reference

26 November 2017

29

1 reference

26 November 2017

8

1 reference

26 November 2017

693-704

1 reference

https://scigraph.springernature.com/pub.10.2165/11584620-000000000-00000

26 November 2017

0 references

cites work

Cardiovascular disease risk profiles.

1 reference

https://api.crossref.org/works/10.2165%2F11584620-000000000-00000

An updated coronary risk profile. A statement for health professionals.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11584620-000000000-00000

Direct medical costs of coronary artery disease in the United States.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11584620-000000000-00000

Lifetime cost of stroke in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11584620-000000000-00000

Long-term cost of stroke subtypes among Medicare beneficiaries.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11584620-000000000-00000

Long-term economic outcomes associated with intensive versus moderate lipid-lowering therapy in coronary artery disease: results from the Treating to New Targets (TNT) Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11584620-000000000-00000

Cost effectiveness of rosuvastatin in treating patients to low-density lipoprotein cholesterol goals compared with atorvastatin, pravastatin, and simvastatin (a US Analysis of the STELLAR Trial).

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11584620-000000000-00000

Cost-effectiveness of intensive atorvastatin therapy in secondary cardiovascular prevention in the United Kingdom, Spain, and Germany, based on the Treating to New Targets study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11584620-000000000-00000

An economic evaluation of atorvastatin for primary prevention of cardiovascular events in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11584620-000000000-00000

Long-term survival after first-ever stroke: the Oxfordshire Community Stroke Project.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11584620-000000000-00000

The central role of the propensity score in observational studies for causal effects

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11584620-000000000-00000

Much ado about two: reconsidering retransformation and the two-part model in health econometrics.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11584620-000000000-00000

Costs of heart disease and risk behaviour: implications for expenditure on prevention.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11584620-000000000-00000

The natural history of prevalent ischaemic heart disease in middle-aged men

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11584620-000000000-00000

Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group

21 January 2018

1 reference

12 December 2020

Primary and subsequent coronary risk appraisal: new results from the Framingham study.

1 reference

12 December 2020

The benefits of treating hyperlipidemia to prevent coronary heart disease. Estimating changes in life expectancy and morbidity

1 reference

12 December 2020

The prognosis of heart failure in the general population: The Rotterdam Study

1 reference

12 December 2020

Forecasting coronary heart disease incidence, mortality, and cost: the Coronary Heart Disease Policy Model

1 reference

12 December 2020

Lifetime medical costs for women: cardiovascular disease, diabetes, and stress urinary incontinence

1 reference

12 December 2020

The development of a simulation model of primary prevention strategies for coronary heart disease

1 reference

12 December 2020

Too much ado about two-part models and transformation? Comparing methods of modeling Medicare expenditures

1 reference

12 December 2020

The development of a simulation model of the treatment of coronary heart disease

1 reference

12 December 2020

The incidence and economic costs of cancer, motor vehicle injuries, coronary heart disease, and stroke: a comparative analysis

1 reference

12 December 2020

10.2165/11584620-000000000-00000

Identifiers

DOI

1 reference

Dimensions Publication ID

26 November 2017

0 references

1 reference